Harvard Bioscience Inventory

Harvard Bioscience's inventory stands at $22M as of June 2026. That compares with $22M in the prior-year period — down 0.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Harvard Bioscience reported $22M in inventory versus $22M a year earlier — a 0.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $22M in the prior-year period — down 0.1% year over year. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Harvard Bioscience's inventory evolved across reporting periods, while the comparison chart places HBIO next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Harvard Bioscience's reading of $22M is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.